Jounce Therapeutics, Inc. (NASDAQ:JNCE) Q3 2019 Earnings Conference Call - Final Transcript
Nov 07, 2019 • 08:00 am ET
Good morning, ladies and gentlemen, and welcome to the Jounce Therapeutics Third Quarter 2019 Earnings Conference Call. [Operator Instructions].
I will now turn the call over to your host, Komal Joshi with Jounce Therapeutics. Please go ahead.
Good morning and thank you for joining us for our third quarter 2019 financial results conference call. This morning, we issued a press release which outlines the topics that we plan to discuss today. The release is available in the Investors & Media section of our website at www.jouncetx.com.
Speaking on today's call will be our CEO and President, Dr. Rich Murray, who will provide an update on our pipeline progress and corporate developments, followed by our CMO, Dr. Beth Trehu, who will provide an update on our clinical activities. And lastly our CFO, Kim Drapkin will review our third quarter financial results and provide an update of our 2019 guidance. We will then open the call for your questions.
Before we begin, I would like to remind everyone that today's discussion will include statements about our future expectations, plans and prospects that constitute forward-looking statements for the purposes of the Safe Harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors including the risk factors discussed in our SEC filings.
In addition, any forward-looking statements represent our views only as of today November 7, 2019 and should not be relied upon as representing our views as of any subsequent date. While we may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so even if our views change.
With that, I will now turn the call over to Rich.
Thanks, Komal, and good morning, everyone. The Jounce team has continued to work diligently on advancing our pipeline and executing on our strategy of developing immunotherapies with the potential to provide long-lasting benefits to cancer patients. Specifically, we're pleased to report the continued progress of our two clinical stage programs vopratelimab or vopra, our ICOS agonist and JTX-4014 our PD-1 inhibitor as well as the further development of our discovery pipeline.
The cornerstone of the vopra clinical development program is ICOS hi CD4 T effector cells, a vopra associated pharmacodynamic biomarker, which is not seen with PD-1 inhibitors. Earlier this year, we presented exciting data from the ICONIC study our Phase I/II vopra clinical trial at AACR showing improved responses, PFS and OS directly linked to the emergence of these cells.
Based on extensive reverse translational analysis from our ICONIC trial presented at several scientific meetings, we've identified two development paths for the vopra program. In the first development path, we're focused on fully realizing the biology of the ICOS hi CD4 T cells, both the induction of the cell population as well as their expansion and sustained activation. To-date the vast majority of IO approaches attempt to enhance CD8 T cells. However, fundamental